Velasco, G. D., Necchi, A., Loriot, Y., Hussain, S. A. (2025). SOGUG-NEOWIN: A phase 2, open-label, multicenter, multinational interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and the combination of ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) harboring FGFR gene alterations.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps4628